New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue grew −91.9% on a year earlier, against −60.8% the quarter before.

Q3 FY2026 and the 4 quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 2 (91.9) (663.9) (0.68)
Q2 FY26 2 (60.8) (489.8) (2.62)
Q1 FY26 2 — 100.0 (7.05)
Q3 FY25 20 — 10.7 0.61
Q2 FY25 5 — (237.4) (4.08)

Against the consensus: revenue missed by 47.1% ($1.6M v $3.1M); adjusted EPS missed by $0.26 (−$0.68 v −$0.42).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Reports Jul 19, 2027 · Q4 FY26 · consensus EPS −$0.55

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 250
Revenue ttm —
Net income ttm —
Free cash flow ttm —
Net debt Q (174)
Valuation
P/E n/m
Forward P/E FY26e n/m
Price / sales 6.7
Forward P/S FY26e Powerpack
Price / FCF —
Price / book 1.4
Financial health
Current ratio Q 4.7 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q —
Growth
Revenue growth FY26e −75.8% (below 0%: weak)
EPS growth FY26e —
EPS growth FY27e —
EPS growth, 5 yrs e —
Insiders
Net bought 12m 71
Sells 12m 0
Buys 12m 6
Owned by insiders 16.6%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Valuation

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — 51 — 12 6 7 (48.5%)
Gross margin, % — — — — — — — — — 100.00 —
EBT — — — — — — — — — 51 —
EBT margin, % — — — — — — — — — 100.00 —
Net income — — — — — — — — — — —
Per share, $
Per share, $ Revenue — — — — — — — — — 21.07 —
Earnings — — — — — — — — — (8.98) —
Cash flow — — — — — — — — — — —
Capex — — — — — — — — — — —
Free cash flow — — — — — — — — — — —
Book value — — — — — — — — — — —
Shares, m — — — — — — — — — 2 —
Valuation, ×
Valuation, × P/E — — — — — — — — — n/m —
P/S — — — — — — — — — 1.84 —
P/B — — — — — — — — — 0.00 —
EV/Sales — — — — — — — — — 0.36 —
EV/FCF — — — — — — — — — 0.00 —
Cash, $m
Cash, $m Operating cash flow — — — — — — — — — — —
Capex — — — — — — — — — — —
Free cash flow — — — — — — — — — — —
Balance, $m
Balance, $m Working capital — — — — — — — — — — —
Net debt — — — — — — — — — — —
Shareholders’ equity — — — — — — — — — — —
Returns, %
Returns, % ROA — — — — — — — — — — —
ROIC — — — — — — — — — — —
ROE — — — — — — — — — — —
People
People Employees — — — — — — — — — — —
Revenue/emp, $m — — — — — — — — — — —
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Scribe Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SABS SAB Biotherapeutics, Inc. $262.2M — (loss-making) 19.9× FY25e — n/m −9.96% (below 0%: shrinking) 100.00% (8,726.07%) Compare
AUTL Autolus Therapeutics PLC Sponsored ADR $260.9M — (loss-making) — (loss-making) +94.57% (above 0%: growing) n/m +75.40% (above 0%: growing) 56.53% (105.57%) Compare
PRLD Prelude Therapeutics Incorporated $260.5M — (loss-making) — (loss-making) −13.12% (below 0%: shrinking) n/m +27.92% (above 0%: growing) 100.00% (252.61%) Compare
EIKN Eikon Therapeutics, Inc. $257.9M — (loss-making) — — n/m −12.03% (below 0%: shrinking) — — Compare
QTTB Q32 Bio Inc. $253.8M 2.5× — (loss-making) −1,928.18% (below 0%: shrinking) n/m −4.44% (below 0%: shrinking) 100.00% 176.03% Compare
CAMP CAMP4 Therapeutics Corporation $251.0M — (loss-making) — (loss-making) +138.87% (above 0%: growing) n/m +20.36% (above 0%: growing) 100.00% (738.76%) Compare
SCTX Scribe Therapeutics Inc. $250.4M — (loss-making) — (loss-making) — n/m — 100.00% (663.94%)
OCGN Ocugen, Inc. $248.6M — (loss-making) — (loss-making) +11.36% (above 0%: growing) n/m −22.15% (below 0%: shrinking) 100.00% (909.94%) Compare
IPSC Century Therapeutics, Inc. $239.7M — (loss-making) — (loss-making) +12,667.72% (above 0%: growing) n/m +11.70% (above 0%: growing) 100.00% 67.95% Compare
Median of peers $255.8M — — +52.97% — +3.63% 100.00% (252.61%)

All 621 Biotechnology stocks →

stockrow.com/SCTX · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com